Prostate cancer is the second most common cancer in men worldwide. The FDA approved docetaxel in 2004 as first-line treatment for men with castrate-refractory prostate cancer (CRPC) and this is now the standard treatment for such patients. Patients with metastatic disease, however, eventually discontinue docetaxel